Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 88

Sort by

Sort Order Select

Journal Articles

Unwinding the genomic threads of monoclonal gammopathy of renal significance through ultra-low pass whole genome sequencing

Blood (2025) 146 (Supplement 1): 3970.

https://doi.org/10.1182/blood-2025-3970

Published: 2025

Journal Articles

Fat pad biopsy versus target organ biopsy in systemic AL amyloidosis detection

Kristina Nasr, Yan Zou, Shahzad Raza, Mazen Hanna, Jack Khouri, Jason Valent, Christy Samaras, Sandra Mazzoni, Cynthia Scott, Kimberly Hamilton, Saveta Mathur, Beth Faiman, Louis Williams, Faiz Anwer, Diana Basali

Blood (2025) 146 (Supplement 1): 3969.

https://doi.org/10.1182/blood-2025-3969

Published: 2025

Journal Articles

Real-world safety and efficacy of BCMA bispecific antibodies in relapsed light chain amyloidosis

Vasil Mico, Raymond Comenzo, Shahzad Raza, Jason Valent, Faiz Anwer, Christy Samaras, Louis Williams, Jack Khouri, Xia Wu, Parva Bhatt, Andreas Klein, Joslyn Rudoni, Teresa Fogaren, Mikhaila Rice, Jonathan Kissam, Sandra Mazzoni

Blood (2025) 146 (Supplement 1): 3961.

https://doi.org/10.1182/blood-2025-3961

Published: 2025

Journal Articles

Real‑world comparison of CAR‑T therapy versus bispecific antibodies in Relapsed/Refractory multiple myeloma

Abdullah Humayun, Mohammad Faizan, Abdul Rafae Faisal, Ahmed Sajid, Zainab Zaib Khan, Asad Zaman, Ali Shan Hafeez, Pramod Singh, Henna Qadri, Akif Rahman, Mehtab Anwar, Khutaija Noor, Abeer Sarwar, Shahzad Raza

Blood (2025) 146 (Supplement 1): 2286.

https://doi.org/10.1182/blood-2025-2286

Published: 2025

Journal Articles

Real-time interleukin-6 (IL-6) kinetics predict cytokine release syndrome (CRS) in patients receiving chimeric antigen receptor (CAR) T-cell therapy for Relapsed/Refractory B-cell malignancies

Agrima Mian, Rafaella Ferreira De Araujo Litvin, Jessica Colon-Franco, Sujata Patil, Megan Molnar, Allison Winter, Sandra Mazzoni, Robert Dean, Louis Williams, Aaron Gerds, John Molina, Shahzad Raza, Faiz Anwer, Deepa Jagadeesh, Betty K. Hamilton, Claudio Brunstein, Brian Hill, Paolo Caimi

Blood (2025) 146 (Supplement 1): 2397.

https://doi.org/10.1182/blood-2025-2397

Published: 2025

Journal Articles

The real-world safety and efficacy of bispecific t-cell engager therapy in systemic AL amyloidosis

Blood (2025) 146 (Supplement 1): 2182.

https://doi.org/10.1182/blood-2025-2182

Published: 2025

Journal Articles

The real-world safety and efficacy of BCMA-directed chimeric antigen receptor T-cell therapy in systemic AL amyloidosis

Blood (2025) 146 (Supplement 1): 2181.

https://doi.org/10.1182/blood-2025-2181

Published: 2025

Journal Articles

Real‑world matched comparison of talquetamab versus teclistamab in Relapsed/Refractory multiple myeloma

Abdul Rafae Faisal, Mohammad Faizan, Abdullah Humayun, Zainab Zaib Khan, Ali Shan Hafeez, Asad Zaman, Ahmed Sajid, Pramod Singh, Henna Qadri, Akif Rahman, Mehtab Anwar, Khutaija Noor, Shahzad Raza

Blood (2025) 146 (Supplement 1): 7577.

https://doi.org/10.1182/blood-2025-7577

Published: 2025

Journal Articles

Infection risk factors and burden in patients treated with T-cell engaging bispecific antibodies for relapsed B-cell lymphoma and multiple myeloma

Blood (2025) 146 (Supplement 1): 2814.

https://doi.org/10.1182/blood-2025-2814

Published: 2025

Journal Articles

Novel method of minimal residual disease testing in myeloma: Liquid biopsies to enumerate and 3D telomere-profiling of circulating tumor cells

Yulia Shifrin, Asieh Alikhah, Zahabiya Husain, Jack Khouri, Louis Williams, Christy Samaras, Shahzad Raza, Faiz Answer, Jason Valent, Beth Faiman, Emmet Samsa, Jessica Jones, Kelly Shepperd, Sabine Mai, Sandra Mazzoni

Blood (2025) 146 (Supplement 1): 2217.

https://doi.org/10.1182/blood-2025-2217

Published: 2025

Journal Articles

Dysregulated proteasome proteostasis acts as a driver of light chain amyloidosis

Sandra Mazzoni, Babal Jha, Louis Williams, Jack Khouri, Christy Samaras, Shahzad Raza, Faiz Anwer, Jason Valent, Arda Durmaz, Yahan Zhang, Kacey O'Donnell

Blood (2025) 146 (Supplement 1): 7473.

https://doi.org/10.1182/blood-2025-7473

Published: 2025

Journal Articles

Subsequent primary malignancies after CAR-T therapy: A study from the US multiple myeloma immunotherapy consortium

Blood (2025) 146 (Supplement 1): 5852.

https://doi.org/10.1182/blood-2025-5852

Published: 2025

Journal Articles

Prognostic factors and survival outcomes of urgent inpatient chemotherapy for relapsed/refractory lymphoma in the modern era

Abhishek Kataria, Mikhaila Rice, Wei Wei, Faiz Anwer, Paolo Caimi, Allison Winter, Robert Dean, Taylor Brooks, Joslyn Rudoni, Jack Khouri, Christy Samaras, Shahzad Raza, Sandra Mazzoni, Jason Valent, Brian Hill, Deepa Jagadeesh

Blood (2025) 146 (Supplement 1): 2737.

https://doi.org/10.1182/blood-2025-2737

Published: 2025

Journal Articles

Patients with multiple myeloma and CKD: Should we really hold off on bispecific therapy in this subgroup?

Kirti Arora, Rishi Chowdhary, Diana Basali, Christy Samaras, Akriti Jain, Deevyashali Parekh, Jason Valent, Jack Khouri, Louis Williams, Sandra Mazzoni, Abhay Singh, Faiz Anwer, Shahzad Raza

Blood (2025) 146 (Supplement 1): 2248.

https://doi.org/10.1182/blood-2025-2248

Published: 2025

Journal Articles

Predictors of early relapse following ciltacabtagene autoleucel: Informing risk-adapted therapy in relapsed/refractory multiple myeloma

Doris Hansen, Lauren Peres, Danai Dima, Saurabh Zanwar, Omar Alexis Castaneda Puglianini, Alicia Richards, Mahmoud Gaballa, Oren Pasvolsky, Aimaz Afrough, Brett Reid, Ariel Grajales-Cruz, Zhuoer Xie, Utkarsh Goel, Aishwarya Sannareddy, Christen Dillard, Christopher Ferreri, Shebli Atrash, Cindy Varga, Andrew Portuguese, Hitomi Hosoya, Lekha Mikkilineni, Nilesh Kalariya, Damian Mikulski, Charlotte Wagner, Christopher Cahoon, Peter Cheng, Christian Gordillo, Eli Zolotov, Evguenia Bhurtel, Jeries Kort, Raffaella Cassano Cassano, Shonali Midha, James Davis, Rebecca Gonzalez, Megan Herr, Hamza Hassan, Sneha Purvey, Marcus Geer, Kimberly Green, Fabiana Perna, Hien Liu, Taiga Nishihori, Jack Khouri, Shahzad Raza, Faiz Anwer, Susan Bal, Omar Nadeem, Ciara Louise Freeman, Rahul Banerjee, Leyla Shune, Ran Reshef, Kenneth Shain, Melissa Alsina, Rachid Baz, Douglas Sborov, Peter Voorhees, Larry Anderson, Luciano Costa, Noa Biran, Shaji Kumar, Frederick Locke, Yi Lin, Surbhi Sidana, Krina Patel

Blood (2025) 146 (Supplement 1): 93.

https://doi.org/10.1182/blood-2025-93

Published: 2025

Journal Articles

Increased risk of gastrointestinal complications in older adults with multiple myeloma: A propensity matched nationwide cohort study

Kirti Arora, Rishi Chowdhary, Aditi Arora, Moath Albliwi, Rachel Mcnulty, Preksha Singh, Juhi Chovatiya, Manzer Ali, Kashish Magnani, Shahzad Raza

Blood (2025) 146 (Supplement 1): 8126.

https://doi.org/10.1182/blood-2025-8126

Published: 2025

Journal Articles

Aberrant clonal plasma cells bypass the proteasome proteostasis by endoplasmic reticulum associated protein degradation

Yahan Zhang, Sandra Mazzoni, Arda Durmaz, Kacey O'Donnell, Christy Samaras, Faiz Anwer, Shahzad Raza, Jason Valent, Jack Khouri, Louis Williams, Babal Jha

Blood (2025) 146 (Supplement 1): 7476.

https://doi.org/10.1182/blood-2025-7476

Published: 2025

Journal Articles

Conditional progression free survival (PFS) in patients with multiple myeloma (MM) after upfront autologous stem cell transplantation (ASCT): A secondary CIBMTR analysis

Utkarsh Goel, Danai Dima, Mohamed Hashem, Kristina Nasr, Hossam M. Ali, Louis Williams, Sandra Mazzoni, Shahzad Raza, Faiz Anwer, Jack Khouri

Blood (2025) 146 (Supplement 1): 5762.

https://doi.org/10.1182/blood-2025-5762

Published: 2025

Journal Articles

Real-world response and toxicity profiles of sequential bispecific antibody therapies in Relapsed/Refractory multiple myeloma

Agrima Mian, Rafaella Ferreira De Araujo Litvin, Kelsey Pandrangi, Kristina Nasr, Sharan Jhaveri, Mikhaila Rice, Joslyn Rudoni, Louis Williams, Christy Samaras, John Molina, Betty K. Hamilton, Shahzad Raza, Faiz Anwer, Jason Valent, Claudio Brunstein, Brian Hill, Paolo Caimi, Sandra Mazzoni

Blood (2025) 146 (Supplement 1): 6376.

https://doi.org/10.1182/blood-2025-6376

Published: 2025

Journal Articles

Safety and efficacy of BCMA directed CAR-T therapy in older patients (Aged ≥ 75) with relapsed or refractory multiple myeloma (RRMM)

Blood (2025) 146 (Supplement 1): 6375.

https://doi.org/10.1182/blood-2025-6375

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Unwinding the genomic threads of monoclonal gammopathy of renal significance through ultra-low pass whole genome sequencing

Fat pad biopsy versus target organ biopsy in systemic AL amyloidosis detection

Real-world safety and efficacy of BCMA bispecific antibodies in relapsed light chain amyloidosis

Real‑world comparison of CAR‑T therapy versus bispecific antibodies in Relapsed/Refractory multiple myeloma

Real-time interleukin-6 (IL-6) kinetics predict cytokine release syndrome (CRS) in patients receiving chimeric antigen receptor (CAR) T-cell therapy for Relapsed/Refractory B-cell malignancies

The real-world safety and efficacy of bispecific t-cell engager therapy in systemic AL amyloidosis

The real-world safety and efficacy of BCMA-directed chimeric antigen receptor T-cell therapy in systemic AL amyloidosis

Real‑world matched comparison of talquetamab versus teclistamab in Relapsed/Refractory multiple myeloma

Infection risk factors and burden in patients treated with T-cell engaging bispecific antibodies for relapsed B-cell lymphoma and multiple myeloma

Novel method of minimal residual disease testing in myeloma: Liquid biopsies to enumerate and 3D telomere-profiling of circulating tumor cells

Dysregulated proteasome proteostasis acts as a driver of light chain amyloidosis

Subsequent primary malignancies after CAR-T therapy: A study from the US multiple myeloma immunotherapy consortium

Prognostic factors and survival outcomes of urgent inpatient chemotherapy for relapsed/refractory lymphoma in the modern era

Patients with multiple myeloma and CKD: Should we really hold off on bispecific therapy in this subgroup?

Predictors of early relapse following ciltacabtagene autoleucel: Informing risk-adapted therapy in relapsed/refractory multiple myeloma

Increased risk of gastrointestinal complications in older adults with multiple myeloma: A propensity matched nationwide cohort study

Aberrant clonal plasma cells bypass the proteasome proteostasis by endoplasmic reticulum associated protein degradation

Conditional progression free survival (PFS) in patients with multiple myeloma (MM) after upfront autologous stem cell transplantation (ASCT): A secondary CIBMTR analysis

Real-world response and toxicity profiles of sequential bispecific antibody therapies in Relapsed/Refractory multiple myeloma

Safety and efficacy of BCMA directed CAR-T therapy in older patients (Aged ≥ 75) with relapsed or refractory multiple myeloma (RRMM)

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only